Legend Biotech (LEGN) disclosed late Monday new results from a phase 3 study showing a single infusion of Carvykti provided "significantly higher" rates of minimal residual disease-negativity in patients with relapsed or lenalidomide-refractory multiple myeloma.
The medication is for patients who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent.
The company said that 89% of evaluable patients achieved minimal residual disease negativity with Carvykti after a three-year follow-up in the study, with the "majority in less than 2 months." The results "add" to the overall survival benefit recently reported.
"The latest MRD data showcases the advances of Carvykti and further demonstrates why it is a leading treatment for patients with multiple myeloma," said Ying Huang, chief executive officer of Legend Biotech.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。